Spotlight Innovation Commences Part 2 of Phase I Cancer Trial

URBANDALE, Iowa, March 10, 2017, STLT, /PRNewswire/  Spotlight Innovation Inc. (OTCQB: STLT) today announced that its subsidiary Celtic Biotech has begun Part 2 of its Phase I dose escalation safety study, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. ImmunoClin Ltd., a company specializing in clinical development, is the contract research organization (CRO) overseeing the study conduct. Part 2 of the Phase I study uses a revised protocol designed to determine whether faster dose escalation can be attained
http://bit.ly/2m89EzG